Novozyme To Set Up Its First Pharmaceutical Company In Tianjin
This article was originally published in PharmAsia News
Executive Summary
Denmark-based Novozyme recently started constructing its biopharmaceutical base in Tianjin's Binhai new district, its first such project in China. This represents the company's second key project after its enzyme formulation plant in the city. With a first phase investment of $70 million, the new facility will mainly produce hyaluronic acid raw drug materials and is expected to start operation by the end of 2010. Novozyme attributes the latest move to Tianjin's solid market conditions and will continue to increase investment if everything goes on track smoothly. (Click here for more - Chinese Language)